证券代码：600222 证券简称：太龙药业 公告编号：2025-050 河南太龙药业股份有限公司 关于为下属全资及控股子公司融资提供担保的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 浙江桐君堂中药饮片有限公司 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 本次担保金额 | 3,000.00 | 万元 | | | | | | | | | | 担 | 保 | 对 | 实际为其提供的担保余额 | 14,610.00 | 万元（含本次） | 象一 | | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | | | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | | | | | | | | 被担保人名称 | 北京新领先医药科技发展 ...

Core Insights - The traditional Chinese medicine sector saw a slight increase of 0.27% on September 29, with Jilin Aodong leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Jilin Aodong (000623) closed at 20.40, with a rise of 6.69% and a trading volume of 477,000 shares, amounting to a transaction value of 956 million yuan [1] - Other notable performers included: - Zhongheng Group (600252) at 2.74, up 3.40% with a volume of 793,500 shares [1] - Tailong Pharmaceutical (600222) at 6.52, up 3.00% with a volume of 226,600 shares [1] - Jinhua Co., Ltd. (600080) at 7.21, up 3.00% with a volume of 125,500 shares [1] Fund Flow Analysis - The traditional Chinese medicine sector experienced a net outflow of 244 million yuan from institutional investors, while retail investors saw a net inflow of 204 million yuan [2] - The main fund inflows and outflows for specific stocks included: - Jilin Aodong had a net inflow of 91.59 million yuan from institutional investors [3] - Yunnan Baiyao saw a net inflow of 26.21 million yuan from institutional investors [3] - Taikang Group (600129) had a net inflow of 6.25 million yuan from institutional investors [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、关联交易基本情况 河南太龙药业股份有限公司（以下简称"公司"）分别于2022年3月23日、2022年4月11日召开第九届董事 会第二次会议和2022年第二次临时股东大会，审议通过了《关于公司接受间接控股股东财务支持暨关联 交易的议案》，同意公司及公司控股子公司向公司间接控股股东郑州高新投资控股集团有限公司（以下 简称"高新投控"）借款不超过12亿元（三年内可在该额度内循环使用），单笔借款的年利率原则上不高 于4.2%，借款额度范围内可分笔支取借款。 公司分别于2022年4月、2022年9月与高新投控签署《统借统还借款合同》，并收到高新投控向公司提供 的4.19亿元、1.57亿元借款，资金成本分别为4.0266%/年、3.2966%/年。 近日，公司根据融资需求向高新投控请示确认借款合同展期期限及利率，并收到高新投控反馈,鉴于高 新投控向公司提供财务支持对应的债券资金已分别于2025年4月1日和2025年8月24日到期并归还完毕， 对公司的借款不再属于统借统还范畴，故无法续签《 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-049 河南太龙药业股份有限公司 关于接受间接控股股东财务支持暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、关联交易基本情况 河南太龙药业股份有限公司（以下简称"公司"）分别于 2022 年 3 月 23 日、2022 年 4 月 11 日召开第九届董事会第二次会议和 2022 年第二次临时股东大会，审议通过了《关于公司接受间接控股股东财 务支持暨关联交易的议案》，同意公司及公司控股子公司向公司间接 控股股东郑州高新投资控股集团有限公司（以下简称"高新投控"） 借款不超过 12 亿元（三年内可在该额度内循环使用），单笔借款的 年利率原则上不高于 4.2%，借款额度范围内可分笔支取借款。 公司分别于 2022 年 4 月、2022 年 9 月与高新投控签署《统借统 还借款合同》，并收到高新投控向公司提供的 4.19 亿元、1.57 亿元 借款，资金成本分别为 4.0266%/年、3.2966%/年。 为进一步支持公司发展和日常生产经营 ...

Core Points - On September 25, 2023, the company announced the issuance of a total of 400 million yuan in the first phase of ultra-short-term financing bonds for the year 2025 in the interbank bond market [2] Summary by Category Company Actions - The company has issued ultra-short-term financing bonds amounting to 400 million yuan [2] - The issuance is part of the company's financing strategy for the year 2025 [2] Market Context - The bonds were issued in the interbank bond market, indicating the company's engagement with broader financial markets [2] - This move may reflect the company's efforts to optimize its capital structure and manage liquidity [2]

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-048 河南太龙药业股份有限公司 关于 2025 年度第一期超短期融资券发行结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）分别于 2025 年 7 月 1 日、2025 年 7 月 17 日召开第九届董事会第三十二次会议和 2025 年第二次临时股东大会，审议通过了《关于拟申请注册发行超 短期融资券的议案》，同意公司向中国银行间市场交易商协会（以下 简称"交易商协会"）申请注册发行总额不超过（含）人民币 8 亿元 的超短期融资券。具体内容详见公司于 2025 年 7 月 2 日、2025 年 7 月 18 日在上海证券交易所网站（www.sse.com.cn）披露的相关公告。 2025 年 9 月，公司收到交易商协会出具的《接受注册通知书》 （中市协注﹝2025﹞SCP239 号），交易商协会同意接受公司科技创 新债券注册，注册金额为 8 亿元，注册额度自《接受注册通知书》落 款之日起 2 年内有效，公 ...

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]

Core Viewpoint - The announcement indicates that Henan Tailong Pharmaceutical Co., Ltd. has canceled the issuance of its first phase of technology innovation bonds for 2025 due to recent market volatility [1] Group 1: Bond Issuance Details - The initial issuance amount for the bonds was set at 0 billion, with a maximum issuance limit of 4 billion [1] - The planned issuance dates were September 18 and September 19, 2025 [1] Group 2: Future Plans - Henan Tailong Pharmaceutical intends to reissue the bonds at a later date after consulting with the lead underwriter [1] - The company will comply with the relevant regulations for the subsequent issuance, repayment, and information disclosure of the technology innovation bonds [1] Group 3: Market Performance - As of the market close, Henan Tailong Pharmaceutical's stock price was reported at 6.43 yuan per share [1]

Core Viewpoint - The company, Henan Tailong Pharmaceutical Co., Ltd., is set to enhance its financing efficiency by accepting a guarantee from its indirect controlling shareholder, Zhengzhou High-tech Investment Holding Group Co., Ltd., for loans up to 697 million yuan, with a guarantee fee not exceeding 13.8592 million yuan [2][4][15]. Summary by Sections 1. Overview of Related Transactions - The indirect controlling shareholder, High-tech Investment Holding, will provide a joint liability guarantee for loans up to 697 million yuan, effective until March 30, 2028 [2][4]. - The total estimated guarantee fee is capped at 13.8592 million yuan, calculated as a fixed fee of 1.35 million yuan plus a 0.7% annual rate [4][10]. 2. Related Party Information - High-tech Investment Holding is the indirect controlling shareholder of the company, classified as a related party under the Shanghai Stock Exchange rules [6][8]. - The company maintains independence in personnel, assets, finance, and operations from High-tech Investment Holding [8]. 3. Financial Impact and Approval Process - The transaction is expected to improve the company's financing operations and is deemed necessary for its business development [15]. - The independent directors reviewed and approved the transaction, confirming that the guarantee fee is fair and does not harm the interests of the company or its minority shareholders [15][16].

Group 1: Changshan Pharmaceutical - The company is preparing for clinical trials of Aibennate peptide for weight loss, with no current plans for oral formulation development [1] - Aibennate peptide is a long-acting GLP-1 receptor agonist, developed through chemical modification of exenatide [1] - The marketing preparation includes team building, product knowledge training, and marketing strategy formulation [1] Group 2: Fosun Pharma - Four innovative drugs approved in the first half of the year are expected to gradually increase sales in the coming months [2] - Innovative drug revenue exceeded 4.3 billion yuan, a year-on-year increase of 14.26%, accounting for over 30% of total drug revenue [2] - The company is actively participating in negotiations for the inclusion of its innovative drugs in insurance and national basic medical insurance directories [2] Group 3: Tiantan Biological Products - The company has established an international cooperation department to enhance its global market presence [3] - Products such as tetanus immunoglobulin and rabies immunoglobulin have already been exported [3] - The company is focused on international certification and registration of key products [3] Group 4: Kangtuo Medical - The US-based subsidiary BIOPLATE has launched a local production line for PEEK plates [4] - The company has completed market access in nearly 40 countries and regions [4] - The marketing of "4D bioactive plates" and PEEK fixation systems is underway in the US [4] Group 5: Tailong Pharmaceutical - The company is focusing on the development of modified new drugs across various therapeutic areas including respiratory, digestive, and oncology [5] - Projects in progress include treatments for Alzheimer's disease and schizophrenia [5] Group 6: Heng Rui Pharmaceutical - The HRS-5635 injection has been included in the list of proposed breakthrough therapies [6][7] - Chronic hepatitis B infection affects approximately 257 million people globally, with a significant mortality rate [7] - There is a pressing need for more effective treatments to achieve functional cure for chronic hepatitis B [7]